XML 49 R39.htm IDEA: XBRL DOCUMENT
v3.25.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 37 Months Ended | 91 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 31, 2017 USD ($) | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Dec. 31, 2020 USD ($) | Jun. 30, 2025 USD ($) milestone product
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Revenues |  | $ 18,306,000 | $ 356,000 | $ 24,743,000 | $ 837,000 |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Agreement termination, term | 15 years |  |  |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Milestone payments received | $ 12,000,000 |  |  |  |  |  | $ 5,000,000
Number of products approved | product |  |  |  |  |  |  | 0
Number of milestones included in transaction price | milestone |  |  |  |  |  |  | 0
Collaborative arrangement transaction price |  |  |  |  |  | $ 17,000,000 |
Revenues |  | $ 0 | $ 0 | $ 0 | $ 0 |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Maximum |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Percentage of net sales per developed licensed product which will trigger royalties by counterparty | 20.00% |  |  |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Maximum | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Development and sales-based milestone payments to be received | $ 60,000,000 |  |  |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Maximum | Achievement Of Commercial Milestones |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Development and sales-based milestone payments to be received | $ 90,000,000 |  |  |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Minimum |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Percentage of net sales per developed licensed product which will trigger royalties by counterparty | 14.00% |  |  |  |  |  |

X
- Definition Agreement Termination, Term + References No definition available. + Details
Name: | sgmo_AgreementTerminationTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreements number of products approved under agreement. + References No definition available. + Details
Name: | sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement transaction price. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty + References No definition available. + Details
Name: | sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty
Namespace Prefix: | sgmo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments received. + References No definition available. + Details
Name: | sgmo_MilestonePaymentsReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of clinical or regulatory milestones included in transaction price. + References No definition available. + Details
Name: | sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |